US-based Revvity, Inc. recently debuted its enhanced imaging portfolio designed to drive innovation across diverse applications in preclinical research with the launch of three systems. These new innovations include the next-generation IVIS Spectrum 2 and the IVIS SpectrumCT 2 imaging systems, further elevating versatility and sensitivity standards in in vivo optical imaging.

Also the Quantum GX3 microCT structural imaging solution has been launched with increased resolution and speed for both in vivo and ex vivo imaging, designed to facilitate researchers studying disease biology or evaluating and fast-tracking therapeutic candidates.

Also making its global debut is the Vega ultrasound system, originally launched in North America in 2022. These cutting-edge technologies were showcased at the World Molecular Imaging Congress (WMIC) recently in Prague, Czech Republic.

These offerings are part of Revvity's best-in-class preclinical imaging portfolio encompassing a comprehensive range of 2D and 3D optical imaging, microCT imaging, ultrasound platforms, reagents, and software tools for data analysis.